Biocytogen Pharmaceuticals (Beijing) (2315) Stock Overview
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
2315 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$46.88 |
| 52 Week High | HK$70.15 |
| 52 Week Low | HK$19.96 |
| Beta | 0.12 |
| 1 Month Change | -5.14% |
| 3 Month Change | -15.30% |
| 1 Year Change | 108.36% |
| 3 Year Change | 129.80% |
| 5 Year Change | n/a |
| Change since IPO | 80.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2315 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 12.5% | -4.2% | -4.7% |
| 1Y | 108.4% | -10.7% | -4.2% |
Return vs Industry: 2315 exceeded the Hong Kong Biotechs industry which returned -10.7% over the past year.
Return vs Market: 2315 exceeded the Hong Kong Market which returned -4.2% over the past year.
Price Volatility
| 2315 volatility | |
|---|---|
| 2315 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.3% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2315 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2315's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,443 | Yuelei Shen | biocytogen.com |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; engages in breeding and selling animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; engages un utilizing the Group’s own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and engages in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary
| 2315 fundamental statistics | |
|---|---|
| Market cap | HK$48.03b |
| Earnings (TTM) | HK$335.21m |
| Revenue (TTM) | HK$1.80b |
Is 2315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2315 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.56b |
| Cost of Revenue | CN¥372.26m |
| Gross Profit | CN¥1.19b |
| Other Expenses | CN¥899.79m |
| Earnings | CN¥290.48m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.65 |
| Gross Margin | 76.18% |
| Net Profit Margin | 18.59% |
| Debt/Equity Ratio | 28.0% |
How did 2315 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 16:45 |
| End of Day Share Price | 2026/06/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| null null | CMB International Securities Limited |